Please check your internet connection and try again.
# Diadzein + Genistein + Palmitoylethanolamide
## Overview
This combination is typically found in dietary supplements. Diadzein and Genistein are isoflavones found in soy, and Palmitoylethanolamide (PEA) is an endogenous fatty acid amide. Their combined use is often explored for potential anti-inflammatory and analgesic effects.
## Primary Indications
This combination is not FDA-approved for any specific medical indication. It is most commonly marketed for:
* Pain management, particularly neuropathic pain.
* Inflammation.
* Menopausal symptom relief.
## Adult Dosing
Dosing varies widely among commercial products. Typical ranges observed in studies or product formulations include:
* **Diadzein:** 20-50 mg daily.
* **Genistein:** 20-50 mg daily.
* **Palmitoylethanolamide (PEA):** 300-1200 mg daily, often divided into two doses.
Specific dosing regimens depend on the product and the intended use. There is no universally established dosing.
## Pediatric Dosing
There is insufficient data to establish pediatric dosing for this combination. Use in pediatric populations is not recommended without further evidence and expert consultation.
## Dose Adjustments
No specific dose adjustments for renal or hepatic impairment are established due to the lack of regulatory approval and standardized dosing. Caution is advised in patients with significant renal or hepatic dysfunction.
## Contraindications
* Hypersensitivity to any component of the product.
* Pregnancy and breastfeeding (due to lack of safety data).
* Hormone-sensitive conditions (e.g., certain breast cancers, uterine fibroids) due to the phytoestrogenic nature of isoflavones, although evidence for clinical impact is debated.
## Adverse Effects
Adverse effects are generally mild and uncommon, but may include:
* **Gastrointestinal:** Nausea, bloating, abdominal discomfort.
* **Allergic reactions:** Rash, itching.
* **Isoflavone-specific:** Menstrual irregularities, breast tenderness.
## Key Drug Interactions
* **Tamoxifen:** Isoflavones may have weak estrogenic effects, potentially interfering with tamoxifen's anti-estrogenic action.
* **Warfarin:** High doses of soy isoflavones have been anecdotally linked to altered INR, though this is not consistently reported.
* **Hormone Replacement Therapy (HRT):** Potential additive estrogenic effects.
## Monitoring
* Monitor for signs of gastrointestinal distress or allergic reactions.
* For patients with hormone-sensitive conditions, monitor for any perceived changes.
* For patients on warfarin, monitor INR closely if concurrent use is considered.
## Clinical Pearls
* This combination is available as a dietary supplement; quality and purity can vary significantly between manufacturers.
* Efficacy and safety are not well-established through rigorous clinical trials for any specific indication.
* Patients should be counseled that these products are not intended to diagnose, treat, cure, or prevent any disease.
* The potential for phytoestrogenic effects of diadzein and genistein should be discussed with patients, particularly those with a history of hormone-sensitive cancers or conditions.
***
*Disclaimer: This information is intended for clinical decision support and does not replace professional medical judgment. Always consult the most current prescribing information or product literature for definitive guidance. It is the responsibility of the prescriber to ensure medical appropriateness and safety.*
